Dr. Rom S. Leidner, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 46
Licensed in Washington since 2005, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OR license MD159938 · WA license MD00044911 (first issued 2005; active) -
Hematology & Oncology Physician
OH license 57.012492
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence Portland Medical Center Portland, OR
Medical groups
- Providence Health and Services Oregon (1,433 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 46
- Services billed
- 384
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 148 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 63 | 38 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $190 in total to this clinician.
| Caris Mpi, Inc. | $162 |
|---|---|
| Astellas Pharma US Inc | $27.63 |
| Food and Beverage | $190 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $277,196 in research payments for these studies, mostly to the institutions running them.
- A Phase Ib study of multivalent autophagosome vaccine, with or without GITR agonist, with sequenced checkpoint inhibition (anti-PD-1) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Incyte Corporation - A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positiv…
Astellas Pharma Global Development - A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
E.r. Squibb & Sons, L.l.c. - This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
Incyte Corporation - Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo Inc. · Recruiting · NCT06731478 - BNT113-01
BioNTech SE - An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of N0112 in Human Leukocyte Antigen-C0802-Positive Adult Subjects with Unresectable, Advanced, and/or Metastatic Sol…
AstraZeneca Pharmaceuticals LP - BNT151-01
BioNTech SE
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.